Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 10/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.43 |
| ▸ | NAT1 | P18440 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15315393 | 0.81 | POLB (0.46) | PIM1GSK3B | |
| SCHEMBL19928705 | 0.81 | POLB (0.46) | PIM1GSK3B | |
| SCHEMBL19928680 | 0.79 | MYC (0.53) | RAB9ANPC1MAOACISD1NAT1 | |
| SCHEMBL19928700 | 0.79 | MYC (0.53) | RAB9ANPC1MAOACISD1NAT1 | |
| SCHEMBL18598096 | 0.75 | IGF1R (0.43) | PIM1PIM2HPGDPIM3AKR1B1 | |
| SCHEMBL13618348 | 0.75 | — | — | |
| SCHEMBL264927 | 0.75 | — | — | |
| SCHEMBL22939019 | 0.75 | — | — | |
| SCHEMBL7121390 | 0.71 | AKR1B1 (0.55) | PIM1PIM2HPGDPIM3AKR1B1 | |
| SCHEMBL13366364 | 0.70 | PIM1 (0.43) | PIM1PIM2HPGDPIM3AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-10005768-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005768-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-06-26 | — | — | US | disclosed |
| US-9908872-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9790228-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170217980-A1 | AMLEXANOX ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-08-03 | — | — | US | disclosed |
| US-20170096421-A1 | Carboxamide Derivatives and Use Thereof | PURDUE PHARMA L.P. | 2017-04-06 | — | — | US | disclosed |
| US-20170096421-A1 | Carboxamide Derivatives and Use Thereof | PURDUE PHARMA L.P. | 2017-04-06 | — | — | US | disclosed |
| US-9493449-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160168157-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC | 2016-06-16 | — | — | US | disclosed |
| US-9296742-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160031873-A1 | Carboxamide Derivatives and Use Thereof | PURDUE PHARMA L.P. | 2016-02-04 | — | — | US | disclosed |
| US-20140206685-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-7709661-B2 | Synthetic methodology for the reductive alkylation at the C-3 position of indoles | WYETH LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080161581-A1 | SYNTHETIC METHODOLOGY FOR THE REDUCTIVE ALKYLATION AT THE C-3 POSITION OF INDOLES | ZIARCO INC. | 2008-07-03 | — | — | US | disclosed |
| US-7282594-B2 | Synthetic methodology for the reductive alkylation at the C-3 position of indoles | WYETH (US) | 2007-10-16 | — | — | US | disclosed |
| US-7230031-B2 | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7230031-B2 | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | PIM1 158/4885PIM2 472/4885HPGD 3572/4885 |
| US-20160168157-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | PIM1 385/4885PIM2 397/4885HPGD 1945/4885 |
| US-20140206685-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | PIM1 385/4885PIM2 397/4885HPGD 1945/4885 |
| US-10005768-B2 | Carboxamide derivatives and use thereof | TRPV1, CACNA1A, SCN10A | PIM1 3791/4885PIM2 3087/4885HPGD 1082/4885 |
| US-20160031873-A1 | Carboxamide Derivatives and Use Thereof | TRPV1, CACNA1A, SCN10A | PIM1 4353/4885PIM2 3754/4885HPGD 477/4885 |
| US-20170096421-A1 | Carboxamide Derivatives and Use Thereof | TRPV1, CACNA1A, SCN10A | PIM1 3791/4885PIM2 3087/4885HPGD 1082/4885 |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | PIM1 158/4885PIM2 472/4885HPGD 3572/4885 |
| US-20170217980-A1 | AMLEXANOX ANALOGS | GPR119, GLP1R, IRS1 | PIM1 2211/4885PIM2 2988/4885HPGD 2325/4885 |
| US-20080161581-A1 | SYNTHETIC METHODOLOGY FOR THE REDUCTIVE ALKYLATION AT THE C-3 POSITION OF INDOLES | IDO1, IDO2, INMT | PIM1 1048/4885PIM2 1529/4885HPGD 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.